期刊文献+

三苯氧胺对乳腺癌术后子宫内膜病变的影响 被引量:1

Effects of tamoxifen on endometrial lesions in breast cancer patients
原文传递
导出
摘要 目的:观察乳腺癌患者术后长期服用三苯氧胺对子宫内膜病变的影响。方法:回顾性分析2002年1月至2004年6月166例乳腺癌患者手术后临床资料。其中102例为雌孕激素受体阳性者,并接受三苯氧胺内分泌治疗作为研究组;其余64例为雌孕激素受体阴性者,未接受三苯氧胺治疗作为对照组。所有患者定期复查阴道超声,发现子宫内膜病变可疑者予宫腔镜检查和诊刮活检术。结果:研究组子宫内膜病变发生率为41.18%(42/102),对照组子宫内膜病变发生率为12.50%(8/64),组间差异有统计学意义(P<0.01)。结论:长期服用三苯氧胺可增加乳腺癌患者术后子宫内膜病变发生率。 Objective To observe the effects of long term use of tamoxifen on endometrial lesions in breast cancer patients. Methods This study retrospectively analyzed the post-operative data of 166 breast cancer patients from January, 2002 to June,2004. The study group included 102 patients who were positive with estrogen and progestogen receptors ,and received tamoxifen treatment. The control group included 64 patients who were negative with estrogen and progestogen receptors,and did not receive tamoxifen treatment. Vaginal B ultrasound was performed periodically in all patients, and hysteroscopy and endometrial pathological biopsy were further performed in the patients with possible endometrial lesions. Results There was a statistically significant difference in the incidence of endometrial lesions between the two group (P〈0.01),with 41. 18% (42/102) in the study group and 12. 50%(8/64) in the control group, respectively. Conclusion The long-term use of tamoxifen during post-operative period in breast cancer patients can increase the incidence of endometrial lesions.
作者 朱娟英
出处 《中国农村卫生事业管理》 2009年第12期938-940,共3页 Chinese Rural Health Service Administration
关键词 乳腺癌 三苯氧胺 子宫内膜病变 病理组织学 breast cancer tamoxifen endometrial lesions pathohistology
  • 相关文献

参考文献1

二级参考文献38

  • 1宋三泰,江泽飞.乳腺癌芳香化酶抑制剂治疗的现状与存在问题[J].中华肿瘤杂志,2005,27(8):510-512. 被引量:13
  • 2Doisneau-Sixou S F,Sergio C M,Carroll J S,et al.Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells[J].Endocr Relat Cancer,2003,10(2):179-186.
  • 3Early Breast Cancer Trialists' Collaborative Group.Ovarian ablation in early breast cancer:overview of the randomised trials[J].Lancet,1996,348(9036):1189-1196.
  • 4Robertson J F,Blamey R W.The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre-and perimenopausal women[J].Eur J Cancer,2003,39 (7):861-869.
  • 5Klijn J G,Blamey R W,Boccardo F,et al.Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trials[J].J Clin Oncol,2001,19(2):343-353.
  • 6Kaufmann M,Jonat W,Blamey R,et al.Survival analyses from the ZEBRA study.goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer[J].Eur J Cancer,2003,39(12):1711-1717.
  • 7Jakesz R,Hausmaninger H,Kubista E,et al.Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,methotrexate,and fluorouracil:evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5[J].J Clin Oncol,2002,20 (24):4621-4627.
  • 8Castiglione-Gertsch M,O'Neill A,Price K N,et al.Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer:a randomized trial[J].J Natl Cancer Inst,2003,95(24):1833-1846.
  • 9Davidson N E,O'Neill A M,Vukov A M,et al.Chemoendocrine therapy for premenopausal women with axillary lymph node-positive,steroid hormone receptor-positive breast cancer:results from INT 0101 (E5188)[J].J Clin Oncol,2005,23 (25):5973-5982.
  • 10Baum M,Hackshaw A,Houghton J,et al.Adjuvant goserelin in pre-menopausal patients with early breast cancer:results from the ZIPP study[J].Eur J Cancer,2006,42(7):895-904.

共引文献12

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部